These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10363854)

  • 21. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
    Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
    Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule.
    Talcott JA; Whalen A; Clark J; Rieker PP; Finberg R
    J Clin Oncol; 1994 Jan; 12(1):107-14. PubMed ID: 8270967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National Trends in Hospitalization for Fever and Neutropenia in Children with Cancer, 2007-2014.
    Lekshminarayanan A; Bhatt P; Linga VG; Chaudhari R; Zhu B; Dave M; Donda K; Savani S; Patel SV; Billimoria ZC; Bhaskaran S; Zaid-Kaylani S; Dapaah-Siakwan F; Bhatt NS
    J Pediatr; 2018 Nov; 202():231-237.e3. PubMed ID: 30029861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Out-patient management of febrile neutropenia in indigent paediatric patients.
    Malik IA
    Ann Acad Med Singap; 1997 Nov; 26(6):742-6. PubMed ID: 9522971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial.
    Orme LM; Babl FE; Barnes C; Barnett P; Donath S; Ashley DM
    Pediatr Blood Cancer; 2014 Aug; 61(8):1427-33. PubMed ID: 24604835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.
    Avilés-Robles MJ; Reyes-López A; Otero-Mendoza FJ; Valencia-Garin AU; Peñaloza-González JG; Rosales-Uribe RE; Muñoz-Hernández O; Garduño-Espinosa J; Juárez-Villegas L; Zapata-Tarrés M
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28251. PubMed ID: 32196898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia.
    Bavle A; Grimes A; Zhao S; Zinn D; Jackson A; Patel B; Porea T; Dutta A; Russell H; Heczey A
    J Pediatr Hematol Oncol; 2018 Oct; 40(7):e415-e420. PubMed ID: 29334532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
    Paganini H; Gómez S; Ruvinsky S; Zubizarreta P; Latella A; Fraquelli L; Iturres AS; Casimir L; Debbag R
    Cancer; 2003 Apr; 97(7):1775-80. PubMed ID: 12655535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia.
    Klaassen RJ; Allen U; Doyle JJ
    J Pediatr Hematol Oncol; 2000; 22(5):405-11. PubMed ID: 11037850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in management of low-risk febrile neutropenia.
    Teuffel O; Sung L
    Curr Opin Pediatr; 2012 Feb; 24(1):40-5. PubMed ID: 22037219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The outpatient management of febrile neutropenia in cancer patients.
    Freifeld AG; Pizzo PA
    Oncology (Williston Park); 1996 Apr; 10(4):599-606, 611-2; discussion 615-6. PubMed ID: 8723296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral administration of cefixime to lower risk febrile neutropenic children with cancer.
    Paganini HR; Sarkis CM; De Martino MG; Zubizarreta PA; Casimir L; Fernandez C; Armada AA; Rodriguez-Brieshcke MT; Debbag R
    Cancer; 2000 Jun; 88(12):2848-52. PubMed ID: 10870071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The costs of treating febrile neutropenia in six U.K. Hospitals.
    Leese B
    Eur J Cancer; 1993; 29A Suppl 7():S15-8. PubMed ID: 7508725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
    Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
    J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An organizational and economic approach in France to the ambulatory treatment of febrile neutropenia].
    Turlure P; Durand-Zaleski I
    Presse Med; 2004 Mar; 33(5):338-42. PubMed ID: 15041886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.